Compare MSS & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | XRTX |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2023 | 2018 |
| Metric | MSS | XRTX |
|---|---|---|
| Price | $0.95 | $2.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 229.5K | 31.8K |
| Earning Date | 03-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,217,480.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.01 | N/A |
| 52 Week Low | $0.11 | $0.35 |
| 52 Week High | $3.96 | $3.60 |
| Indicator | MSS | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 49.37 |
| Support Level | $0.83 | $1.98 |
| Resistance Level | $1.03 | $3.03 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 7.05 | 40.65 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.